Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

G. Zugmaier · SciRah

Researcher profile · Semantic Scholar

G. Zugmaier

Share profile

G. Zugmaier — researcher profile on SciRah

h-index: 51
Works: 209
Citations: 14K

Most-cited papers

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
M. Topp, N. Gokbuget, A. Stein, G. Zugmaier +21 more
2015The Lancet Oncology1,141 citations
Semantic Scholar
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
N. Gokbuget, H. Dombret, M. Bonifacio, A. Reichle +14 more
2018Blood797 citations Open access
Semantic Scholar
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
A. von Stackelberg, F. Locatelli, G. Zugmaier, R. Handgretinger +19 more
2016Journal of Clinical Oncology539 citations Open access
Semantic Scholar
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
M. Goebeler, S. Knop, A. Viardot, P. Kufer +20 more
2016Journal of Clinical Oncology388 citations
Semantic Scholar
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
P. Brown, Ling-Yun Ji, Xinxin Xu, M. Devidas +12 more
2021Journal of the American Medical Association (JAMA)339 citations Open access
Semantic Scholar
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
F. Locatelli, G. Zugmaier, C. Rizzari, J. Morris +18 more
2021Journal of the American Medical Association (JAMA)319 citations Open access
Semantic Scholar
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
M. Topp, J. Duell, G. Zugmaier, M. Attal +13 more
2020Journal of Clinical Oncology260 citations
Semantic Scholar
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka, P. Kufer, R. Kischel, G. Zugmaier +13 more
2016Leukemia239 citations
Semantic Scholar
The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types
H. Einsele, H. Borghaei, R. Orlowski, M. Subklewe +5 more
2020Cancer221 citations Open access
Semantic Scholar
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
G. Zugmaier, N. Gokbuget, M. Klinger, A. Viardot +13 more
2015Blood157 citations Open access
Semantic Scholar
Harnessing T cells to fight cancer with BiTE® antibody constructs – past developments and future directions
M. Klinger, J. Benjamin, R. Kischel, S. Stienen +1 more
2016Immunological Reviews156 citations
Semantic Scholar
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
E. Mejstříková, O. Hrušák, M. Borowitz, J. Whitlock +6 more
2017Blood Cancer Journal138 citations Open access
Semantic Scholar
Blinatumomab Treatment of Older Adults With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: Results From Two Phase 2 Studies
H. Kantarjian, A. Stein, R. Bargou, C. García +8 more
2016Cancer92 citations Open access
Semantic Scholar
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse
L. Hogan, Patrick A. Brown, Ling-Yun Ji, Xinxin Xu +14 more
2023Journal of Clinical Oncology91 citations Open access
Semantic Scholar
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
F. Locatelli, G. Zugmaier, Noemi Mergen, P. Bader +7 more
2020Blood Cancer Journal88 citations Open access
Semantic Scholar
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
N. Gokbuget, G. Zugmaier, M. Klinger, P. Kufer +10 more
2017Haematologica87 citations Open access
Semantic Scholar
Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study.
M. Subklewe, Giulia Magno, C. Gebhardt, V. Bücklein +8 more
2024European Journal of Cancer86 citations Open access
Semantic Scholar
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia
N. Gokbuget, G. Zugmaier, H. Dombret, A. Stein +11 more
2020Leukemia and Lymphoma81 citations Open access
Semantic Scholar
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
L. Gore, F. Locatelli, G. Zugmaier, R. Handgretinger +6 more
2018Blood Cancer Journal79 citations Open access
Semantic Scholar
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
Virginie Nägele, Andrea Kratzer, G. Zugmaier, C. Holland +7 more
2017Experimental Hematology & Oncology74 citations Open access
Semantic Scholar
Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
F. Locatelli, G. Zugmaier, Noemi Mergen, P. Bader +9 more
2022Blood Advances72 citations Open access
Semantic Scholar
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
N. Gokbuget, H. Dombret, S. Giebel, Monika Bruggemann +12 more
2019Hematology69 citations Open access
Semantic Scholar
Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events.
M. Klinger, G. Zugmaier, Virginie Nägele, M. Goebeler +6 more
2019Cancer Research68 citations
Semantic Scholar
Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
A. Stein, H. Kantarjian, N. Gokbuget, R. Bargou +7 more
2019Biology of Blood and Marrow Transplantation65 citations Open access
Semantic Scholar
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
E. Jabbour, G. Zugmaier, V. Agrawal, P. Martínez-Sánchez +23 more
2024American journal of hematology/oncology60 citations Open access
Semantic Scholar
Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
N. Gokbuget, H. Dombret, M. Bonifacio, A. Reichle +12 more
201552 citations
Semantic Scholar
Blinatumomab in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia
M. Queudeville, P. Schlegel, A. Heinz, Teresa Lenz +11 more
2020European Journal of Haematology50 citations Open access
Semantic Scholar
Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study.
M. Topp, J. Duell, G. Zugmaier, M. Attal +13 more
2019Journal of Clinical Oncology48 citations
Semantic Scholar
Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia
M. Queudeville, A. Stein, Franco Locatelli, M. Ebinger +7 more
2023Cancer44 citations Open access
Semantic Scholar
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.
A. Pearson, Nicole Scobie, K. Norga, Franca Ligas +35 more
2019European Journal of Cancer43 citations Open access
Semantic Scholar
Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
G. Zugmaier, M. Klinger, M. Schmidt, M. Subklewe
2015Molecular Immunology37 citations
Semantic Scholar
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study
N. Boissel, S. Chiaretti, C. Papayannidis, J. Ribera +9 more
2023Blood Cancer Journal36 citations Open access
Semantic Scholar
Impact of Philadelphia chromosome‐like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study
E. Jabbour, K. Patel, N. Jain, D. Duose +9 more
2021American journal of hematology/oncology29 citations Open access
Semantic Scholar
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
F. Locatelli, J. Whitlock, C. Peters, Christiane Chen-Santel +15 more
2020Leukemia26 citations Open access
Semantic Scholar
Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
M. Topp, N. Gokbuget, G. Zugmaier, A. Stein +6 more
2020Cancer26 citations Open access
Semantic Scholar
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
M. Topp, M. Stelljes, G. Zugmaier, P. Barnette +8 more
2017Leukemia26 citations Open access
Semantic Scholar
Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia
F. Locatelli, C. Eckert, O. Hrušák, B. Buldini +6 more
2022Pediatric Blood & Cancer25 citations Open access
Semantic Scholar
Blinatumomab for Minimal Residual Disease (MRD) in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Median Overall Survival (OS) Is Not Reached in Complete MRD Responders at a Median Follow-up of 53.1 Months
N. Goekbuget, H. Dombret, G. Zugmaier, M. Bonifacio +6 more
2018Blood25 citations Open access
Semantic Scholar
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.
E. Jabbour, F. Lussana, P. Martínez-Sánchez, A. Torrent +29 more
2025The Lancet Haematology23 citations
Semantic Scholar
Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate
E. Jabbour, I. Aldoss, S. Fleming, A. Bajel +10 more
2022Blood20 citations Open access
Semantic Scholar
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
N. Gokbuget, H. Kantarjian, M. Brüggemann, A. Stein +12 more
2019Blood Advances20 citations Open access
Semantic Scholar
Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia
N. Gokbuget, H. Dombret, S. Giebel, M. Brüggemann +11 more
2019European Journal of Haematology19 citations Open access
Semantic Scholar
Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation
M. Algeri, Michele Massa, D. Pagliara, V. Bertaina +16 more
2024Haematologica17 citations Open access
Semantic Scholar
Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
M. Topp, A. Stein, N. Gokbuget, H. Horst +6 more
2021Cancer Medicine16 citations Open access
Semantic Scholar
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL
F. Locatelli, G. Zugmaier, C. Rizzari, J. Morris +18 more
2022Leukemia14 citations Open access
Semantic Scholar
Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
Pilar Martínez Sánchez, G. Zugmaier, Paul R. Gordon, E. Jabbour +12 more
2022Blood14 citations Open access
Semantic Scholar
Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children's Oncology Group Study AALL1731
Rachel E. Rau, S. Gupta, J. Kairalla, K. Rabin +26 more
2024Blood12 citations
Semantic Scholar
Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor and Molecularly Resistant Acute Lymphoblastic Leukemia (R/R ALL): Updated Analysis of 110 Patients Treated in an Expanded Access Study (RIALTO)
F. Locatelli, G. Zugmaier, P. Bader, S. Jeha +6 more
2019Blood12 citations
Semantic Scholar
CD19 expression in pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia pre‐ and post‐treatment with blinatumomab
E. Mejstříková, M. Klinger, Ana Marković, G. Zugmaier +1 more
2021Pediatric Blood & Cancer11 citations Open access
Semantic Scholar
Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B‐ALL
P. Brown, G. Zugmaier, L. Gore, C. Tuglus +1 more
2019British Journal of Haematology11 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Topp×16
Invite
M. Topp — researcher profile on SciRah
N. Gokbuget×15
Invite
N. Gokbuget — researcher profile on SciRah
R. Bargou×12
Invite
R. Bargou — researcher profile on SciRah
M. Brüggemann×12
Invite
M. Brüggemann — researcher profile on SciRah

×9

Invite

H. Dombret — researcher profile on SciRah

Invite

H. Horst — researcher profile on SciRah

H. Kantarjian×8

Invite

H. Kantarjian — researcher profile on SciRah

A. von Stackelberg×8

Invite

A. von Stackelberg — researcher profile on SciRah

Invite

M. Klinger — researcher profile on SciRah

Invite

A. Stein — researcher profile on SciRah

F. Locatelli×7

Invite

F. Locatelli — researcher profile on SciRah

R. Handgretinger×7

Invite

R. Handgretinger — researcher profile on SciRah